Thermo Fisher stock gains as conference outlook and dividend support valuation

Published on 09/15/2026 at 23:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Thermo Fisher stock rose around 3 percent on September 15, 2026, as management reiterated stronger growth and a full-year organic revenue outlook of about 4 percent. Recent results showed Q2 2026 revenue up 10.5 percent year over year and adjusted EPS of 6.03 dollars.

Wissenschaftler arbeiten in modernem Biotech-Labor mit Analysegeräten und Probenbehältern — Fotorealistisches Laborbild zu Thermo Fisher Sci. US8835561023 zeigt moderne Analysegeräte und Wissenschaftler bei der Probenanalyse, Illustration mit AI erstellt.

Thermo Fisher Scientific stock (ISIN US8835561023) traded at USD 628.50 on the New York Stock Exchange near a 52-week high of USD 647.00 as of September 15, 2026, reflecting a stronger growth outlook and solid investor demand.

Conference comments reinforce growth and guidance

On September 15, 2026, Thermo Fisher Scientific told investors at the Morgan Stanley 24th Annual Global Healthcare Conference that its business is entering a stronger phase, helped by improving demand, solid execution and recent acquisitions, and that orders are running ahead of revenue, supporting future growth, according to Investing.com.

The company said that as it exited the second quarter of 2026 it was back to 5 percent organic revenue growth for the quarter, with earnings per share up 13 percent year over year, and it raised its full-year outlook to about 4 percent organic revenue growth, according to Investing.com.

Recent quarterly figures and dividend support the story

Thermo Fisher’s most recent reported quarter, Q2 2026, showed adjusted earnings per share of USD 6.03, beating the consensus estimate of USD 5.71 by USD 0.32, while revenue reached USD 11.99 billion versus expectations of USD 11.71 billion, with revenue up 10.5 percent year over year, according to MarketBeat.

For full-year 2026, Thermo Fisher has guided to adjusted EPS in a range of USD 24.93 to USD 25.33, and analysts as a group expect around USD 25.13 EPS for the current year, according to MarketBeat.

Thermo Fisher also declared a quarterly dividend of USD 0.47 per share, with an ex-dividend date of September 15, 2026 and a payout date of October 15, 2026, corresponding to an annualized dividend of USD 1.88 and a yield of about 0.3 percent at recent prices, according to MarketBeat.

Analyst consensus and valuation context

Analyst coverage remains supportive: a consensus of 29 analysts rates Thermo Fisher stock as Buy, with an average target price of USD 645.15, a high target of USD 750.00 and a low target of USD 520.00, implying around 5.1 percent upside to the average target from a last close of USD 613.62, according to MarketScreener.

Within that consensus, recent actions include UBS upgrading Thermo Fisher Scientific to Buy from Neutral and raising its price target to USD 730 from USD 540, Baird lifting its target to USD 686 from USD 652 while keeping an Outperform rating, and HSBC increasing its target to USD 690 from USD 660 while maintaining a Buy recommendation, according to MarketScreener.

In terms of valuation, Thermo Fisher shares trade at a price-to-earnings ratio of about 32.9 times according to an analysis accompanying the Morgan Stanley conference coverage, which some data providers characterize as a premium to certain fair value estimates, highlighting execution risk if growth were to slow, according to Investing.com.

Stock price and trading snapshot

Per recent market data, Thermo Fisher Scientific stock closed at USD 613.62 on the New York Stock Exchange on September 14, 2026, before moving higher to around USD 628.50 in subsequent trading, which is within roughly 3 percent of the cited 52-week high of USD 647.00, and the company’s market capitalization stands at about USD 232.5 billion based on that conference-day pricing, according to Investing.com.